Alembic Pharma's Q2 FY25 net profit rose 12% to Rs. 153 crore, fueled by strong branded sales.

Alembic Pharma reported a 12% year-on-year increase in net profit to Rs. 153 crore for Q2 FY25, driven by strong performance in its branded business, particularly in specialty and animal health segments. Revenue rose 3% to Rs. 1,648 crore. The US generics division grew 5%, while the animal health segment saw a 20% increase. The company aims to boost growth through new product launches and enhanced capabilities.

November 07, 2024
4 Articles

Further Reading